Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | NMT1 | P30419 | 5/20 | 0.46 |
| ▸ | NMT2 | O60551 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9425211 | 1.00 | METAP2 (0.48) | METAP2NMT1NMT2SIGMAR1REN | |
| SCHEMBL8056055 | 1.00 | METAP2 (0.48) | METAP2NMT1NMT2SIGMAR1REN | |
| SCHEMBL10431764 | 0.89 | EPHX1 (0.50) | METAP2NMT1NMT2SIGMAR1REN | |
| SCHEMBL8043089 | 0.78 | METAP2 (0.40) | METAP2RENEPHX1DPP7 | |
| SCHEMBL10632207 | 0.78 | REN (0.50) | METAP2NMT1NMT2SIGMAR1REN | |
| SCHEMBL10632213 | 0.78 | REN (0.50) | METAP2NMT1NMT2SIGMAR1REN | |
| SCHEMBL18559838 | 0.78 | CHRNB2 (0.55) | NMT1NMT2SIGMAR1CHRNB2CHRNB4 | |
| SCHEMBL8696270 | 0.78 | SIGMAR1 (0.49) | NMT1NMT2SIGMAR1EPHX1ADAMTS4 | |
| SCHEMBL3723188 | 0.77 | TDP1 (0.44) | EPHX1 | |
| SCHEMBL8061026 | 0.77 | METAP2 (0.42) | METAP2SIGMAR1RENEPHX1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588196-B1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN INC (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-2588196-B1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN INC (US) | 2018-01-24 | — | — | EP | disclosed |
| US-8901159-B2 | Inhibition of inflammation by simultaneous blockade of multiple prostanoid receptors | ALLERGAN, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| CN-103998031-A | Fatty acid amide hydrolase inhibitors for the treatment of pain | ALLERGAN INC | 2014-08-20 | — | — | CN | disclosed |
| US-20140187596-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2588196-A2 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | Allergan, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| CN-103079565-A | Inhibition of inflammation bysimultaneous blockade of multiple prostanoid receptors | ALLERGAN INC | 2013-05-01 | — | — | CN | disclosed |
| US-20120329843-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | ALLERGAN, INC. | 2012-12-27 | — | — | US | disclosed |
| WO-2012162416-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120077857-A1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012003477-A2 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | ALLERGAN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-7868032-B2 | Prostamide receptor antagonists | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868032-B2 | Prostamide receptor antagonists | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20080096240-A1 | NOVEL PROSTAMIDE RECEPTOR ANTAGONISTS | WOODWARD DAVID F | 2008-04-24 | — | — | US | disclosed |
| US-20080096240-A1 | NOVEL PROSTAMIDE RECEPTOR ANTAGONISTS | WOODWARD DAVID F | 2008-04-24 | — | — | US | disclosed |
| US-5153327-A | 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E. R. SQUIBB & SONS, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5100889-A | Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329843-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | FAAH, FAAH2, HRH2 | METAP2 2900/4885NMT1 889/4885NMT2 742/4885 |
| US-20140187596-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | FAAH, FAAH2, HRH2 | METAP2 2900/4885NMT1 889/4885NMT2 742/4885 |
| US-20080096240-A1 | NOVEL PROSTAMIDE RECEPTOR ANTAGONISTS | PTGIR, PTGER1, TBXA2R | METAP2 3020/4885NMT1 1190/4885NMT2 1208/4885 |
| US-20120077857-A1 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS | LTB4R2, LTB4R, PTGIR | METAP2 1714/4885NMT1 1496/4885NMT2 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.